Media ReleasesLifeHealthcare

View All LifeHealthcare News


LifeHealthcare Announces the Right to Promote Spinal Allograft Biologics Range Acquired from Australian Biotechnologies

LifeHealthcare Announces the Right to Promote Spinal Allograft Biologics Range Acquired from Australian Biotechnologies

LifeHealthcare (ASX:LHC) has today acquired the rights from Point Blank Medical to promote the Australian Biotechnologies (Aus Bio) spinal allograft biologics range and entered into a non-stocking commission only ten year distribution agreement with Aus Bio commencing 1 November 2017.

The long term partnership with Aus Bio forms a key element of LifeHeathcare’s biologics strategy, complementing LifeHealthcare’s existing synthetics biologics offering and strengthening LifeHealthcare’s spine market share in Australia. Aus Bio is a leading provider of allograft biologics in Australia and the partnership with LifeHealthcare will expand market coverage for the Allovance allograft portfolio.


For further information please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.